GlassScriptPhysician profile
William D Fuchs
NPI 1417941527
$437.37
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2020: $17.71 · 2021: $141 · 2022: $51.82.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $169.51 | 2019 | |
| Sanofi Pasteur INC. | $89.87 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.53 | 2019-2021 | |
| Kaleo, INC. | $35.10 | 2020-2021 | |
| Glaxosmithkline, LLC. | $32.41 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $21.89 | 2021 | |
| Seqirus USA INC | $19.09 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $15.97 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Fuchs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.